Beta Finch - Altria - MO - EN

More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Altria's third quarter 2026 results, and there's a lot on the table — from a lawsuit against the FDA to a brand-new flavor lineup for nicotine pouches. I'm Alex, here with Jordan, and we're going to break it all down for you.

**JORDAN:** Before we get into it — quick reminder, Alex, you know the drill.

**ALEX:** Right, right. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Perfect. Okay, let's get into Altria's numbers.

**ALEX:** So headline first: adjusted diluted EPS grew 4.8% in Q3, and 5.1% through the first nine months of the year. That's solid growth for a company that's often thought of as slow and steady.

**JORDAN:** And here's the thing that jumped out at me — they actually raised guidance. Full-year adjusted EPS is now expected between $5.66 and $5.74, which works out to 4.5% to 6% growth off last year's $5.42. That's up from their original range of 2.5% to 5%. So management is feeling pretty confident here.

**ALEX:** Yeah, and that confidence is coming largely from the smokeable products segment, which is still the earnings engine for Altria. Adjusted operating company income there grew 3.9% to $3.1 billion in the quarter. Margins expanded too, up to 64.5%.

**JORDAN:** What's interesting is how they're doing it. This isn't just pure pricing power — it's a "total portfolio" strategy. Marlboro's holding the premium end, but they've also got Basic gaining share in the discount segment. Basic's retail share jumped 1.8 points year-over-year as more price-pressured smokers trade down.

**ALEX:** And then there's the new kid — Marlboro Cowboy Cut. It's basically a lower-priced premium option designed to keep value-conscious Marlboro smokers in the franchise instead of losing them to discount brands entirely. It's already in about 100,000 stores, roughly 75% of cigarette volume nationally.

**JORDAN:** Smart playbook, honestly. They've done this before with Marlboro Special Select and Marlboro Black — launch at an introductory price, then gradually take pricing up over time once it's established. And it seems to be working — Marlboro's share of the premium segment hit 60%, up slightly both year-over-year and sequentially.

**ALEX:** Now let's talk about the smoke-free side of the business, because this is where things get really interesting strategically. On! nicotine pouches — shipment volume was up 13.3% in the quarter to 47.8 million cans.

**JORDAN:** But retail share only ticked up 0.1 point year-over-year, and was actually down 0.3 sequentially. That tells you this category is getting fiercely competitive. Everybody's throwing flavors and higher nicotine strengths at the wall right now.

**ALEX:** Which is exactly what Altria's subsidiary Helix is doing in response — they just rolled out on! PLUS 12-milligram nationally, and they're adding new flavors: Blueberry Mint and Mango Pineapple hit shelves this month, with Watermelon Mint coming in November.

**JORDAN:** And don't sleep on the marketing push either — they hosted something called the "on!vitational," an invite-only golf tournament in Palm Beach. It's meant to be a recurring, multiyear brand platform. Altria's clearly trying to build lifestyle equity around on!, not just compete on nicotine strength and flavor.

**ALEX:** Now, here's the part of this call I found most newsworthy — the regulatory fight. Altria's Helix and NJOY subsidiaries actually sued the FDA this quarter.

**JORDAN:** Yeah, this is a big deal. The lawsuit is asking a court to force the FDA to stick to the 180-day review timeline that Congress set for product authorizatio

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Altria Group's second quarter 2026 results. I'm Alex, joined as always by Jordan. And before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Good to be here, Alex. And there's actually a lot to unpack this quarter — Altria raised guidance, but the story underneath it is more nuanced than the headline suggests.

ALEX: Let's start with the numbers. Adjusted diluted EPS came in at $1.48 for the quarter, up 2.8%. For the first half of the year, that's $2.80, up a healthier 4.9%. And on the back of that first-half strength, Altria narrowed — and actually raised the low end of — full-year guidance to a range of $5.61 to $5.72, which works out to 3.5% to 5.5% growth off last year's base.

JORDAN: Right, but here's the interesting wrinkle — one analyst on the call pointed out that even with that raised low end, it's still below what they delivered in the first half. So the second-half math implies things moderate a bit. CEO Sal Mancuso's answer basically boiled down to: the consumer is still under pressure — elevated gas prices, inflation — and they're stepping up investment behind new launches, so don't expect the same pace of growth to just continue in a straight line.

ALEX: That's a good instinct as a listener — when a company raises guidance but the low end still trails first-half performance, it's worth asking why. In this case it sounds like a mix of planned investment spend and just conservative phasing.

JORDAN: Exactly. Now let's talk about where the real growth engine is: smokeable products. That segment's adjusted operating income grew 4.2% in the first half, with margins expanding to nearly 65%. Cigarette volume declines are actually moderating — down about 5% industry-wide when you adjust for inventory, and that's the fourth straight quarter of that decline rate improving.

ALEX: Why is that happening? Management pointed to something pretty specific — fewer smokers switching over to illicit flavored disposable vapes, largely because of stepped-up enforcement. Federal seizures topped $250 million this quarter alone, plus a Minnesota AG lawsuit against a major illicit vape manufacturer.

JORDAN: Which is a fascinating dynamic — Altria's traditional cigarette business is getting a tailwind from regulators cracking down on unregulated vape products. That's basically the whole thesis of tobacco harm reduction policy playing out in real time, just not in the direction some might expect.

ALEX: Meanwhile, within cigarettes, there's a real trade-down story happening. Discount segment share grew 2.6 points as lower-income consumers feel the pinch. Marlboro held its premium leadership — 59.6% share of premium — but its overall share dipped 1.5 points as some smokers shift to value options.

JORDAN: And Altria's playing both sides of that. They launched Marlboro Cowboy Cut — a value-oriented Marlboro line tied to America's 250th anniversary, clever branding there — while also growing their Basic discount brand, which saw share up 2.3 points year-over-year. Management was clear: the strategy is to participate in discount without accelerating the category's growth, protecting Marlboro's premium position as much as possible.

ALEX: Let's shift to the smoke-free side, because this is where the long-term story lives. The oral tobacco segment actually had a rough quarter on paper — adjusted OCI down 8% — but that's largely due to tough prior-year comparisons and heavy investment behind on! PLUS, their new nicotine pouch line.

JORDAN: Right, and context matters here. Nicotine pouches are now nearly 60% of the enti

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear, actionable insights. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Altria Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including a CEO transition and some fascinating market dynamics in both cigarettes and nicotine pouches.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now, let's talk numbers first. Altria delivered a solid start to 2026 with adjusted diluted EPS growing 7.3% in Q1. They're maintaining their full-year guidance of $5.56 to $5.72 per share, which represents 2.5% to 5.5% growth.

**ALEX:** That's a strong performance, but what really caught my attention was the underlying story about consumer behavior. Jordan, can you break down what's happening in the cigarette market?

**JORDAN:** Sure thing. So there are two major trends colliding here. First, we're seeing moderation in the e-vapor category - particularly those illicit flavored disposable products that have been stealing cigarette smokers for years. Federal and state enforcement is finally having an impact, and it looks like the category may have hit a saturation point.

**ALEX:** Which is helping cigarette volumes, right? They declined only 4% when adjusted for trade inventory movements, compared to much steeper declines we've seen in recent years.

**JORDAN:** Exactly. But here's the fascinating part - all of this volume improvement is happening in the discount segment, not premium. Consumers are under serious economic pressure. Gas prices spiked, inflation is still biting, and people are trading down to cheaper brands.

**ALEX:** And Altria is capturing that trade-down with their Basic brand. The numbers here are pretty impressive - Basic grew 2.4 share points year-over-year in the discount segment. Meanwhile, Marlboro actually lost 1.4 share points overall but gained in the premium segment specifically.

**JORDAN:** That's the beauty of their portfolio strategy. They're essentially playing both ends of the market. When premium smokers stay loyal, Marlboro captures them. When economic pressure forces people to trade down, Basic is there waiting.

**ALEX:** Now let's talk about the growth story - oral nicotine pouches. This category is absolutely exploding. Jordan, what's happening with their on! brand?

**JORDAN:** The oral nicotine pouch segment now represents 58% of the total oral tobacco category - that's remarkable growth. Altria's on! portfolio shipped nearly 18% more volume, hitting over 46 million cans in Q1. They launched on! PLUS nationwide in March, and it's already in about 100,000 stores.

**ALEX:** What makes on! PLUS special?

**JORDAN:** Two things: it's the first and only product authorized under the FDA's pilot program for nicotine pouches, which should give them a regulatory advantage. And they're marketing it as "the softest pouch on the planet" using their proprietary NICOSILK technology. They're really trying to differentiate on the user experience.

**ALEX:** Speaking of the FDA, there was interesting commentary about the regulatory environment. CEO William Gifford - and by the way, this was his final earnings call - was pushing hard for the FDA to streamline authorizations for e-vapor products.

**JORDAN:** Right, and his logic makes sense. The e-vapor category is still about 70% illicit products. Gifford argued that faster authorizations combined with sustained enforcement could create a compliant marketplace where authorized manufacturers can serve adult consumers with quality products.

**ALEX:** Let's talk about that CEO transition. Gifford is stepping d

This episode includes AI-generated content.

**Beta Finch Podcast Script: Altria (MO) Q4 2025 Earnings**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into tobacco giant Altria's fourth quarter 2025 results. Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex. And wow, what a quarter for Altria. The company delivered some solid financials but also took a massive $1.3 billion impairment charge on their e-vapor business. That's not exactly chump change.

ALEX: Absolutely not. Let's start with the big picture numbers. Altria grew adjusted earnings per share by 4.4% for the full year and returned a whopping $8 billion to shareholders through dividends and share buybacks. That's serious cash returning to investors.

JORDAN: Right, and they're guiding for 2026 EPS between $5.56 and $5.72, which represents 2.5% to 5.5% growth. But here's the interesting part - CEO Billy Gifford said that growth will be "weighted to the second half of the year." That suggests a slower start to 2026.

ALEX: That timing issue ties into one of their big strategic moves. Altria is investing heavily in what they call "import-export capabilities" - basically a duty drawback program where they can manufacture cigarettes for international markets and then reimport them to get tax benefits. It's a complex play, but CFO Sal Mancuso said it has a payback period of less than a year.

JORDAN: That's actually pretty clever from a financial engineering standpoint. But let's talk about the elephant in the room - that $1.3 billion e-vapor impairment. They acquired NJOY to get into the vaping space, but the market is absolutely dominated by illegal flavored disposables from China.

ALEX: Exactly. Gifford said illegal products represent about 70% of the e-vapor category. Think about that - seven out of ten vaping products sold in the US are essentially operating outside FDA regulations. That makes it nearly impossible for legitimate companies like Altria to compete profitably.

JORDAN: But there might be a silver lining here. The company is seeing early signs that federal enforcement is starting to bite. Disposable e-vapor volume growth slowed from over 50% in 2024 to about 30% in 2025. Plus, Congress allocated at least $200 million in tobacco user fees specifically for enforcement activities.

ALEX: That enforcement angle is crucial for understanding Altria's strategy. They're basically saying "we'll wait on the sidelines until the government cleans up the illegal competition." Meanwhile, they're focusing on their nicotine pouch business, which is actually performing pretty well.

JORDAN: Speaking of nicotine pouches, their ON! brand is interesting. They got FDA authorization for ON! PLUS in December - that's their premium product with what they call "innovative pouch material and smooth flavor." They're positioning it as a premium option that can command higher prices than their classic ON! pouches.

ALEX: The numbers back that up. Helix, which makes the ON! products, shipped over 177 million cans for the full year, up about 11%. And while competitors were cutting prices - down 12% year-over-year according to Altria - they actually raised ON! prices by 3%.

JORDAN: But let's be real about the core business. Cigarette volumes declined 10% for the full year. That's a serious headwind. Even more concerning, Marlboro's retail share dropped below 40% for the first time ever.

ALEX: That Marlboro number caught my attention too. But Gifford pushed back on concerns during the Q&A, saying they're focused on "maximizing profitability over the long term" rather than chasing market share. They're also aggressively promoting their Basic discount brand in about 30,000 stores t

This episode includes AI-generated content.

Stay tuned for AI-powered earnings analysis from Beta Finch.

This episode includes AI-generated content.